OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, October 16, 2012

The Role of Appendectomy for Mucinous Ovarian Neoplasms



The Role of Appendectomy for Mucinous Ovarian Neoplasms



Abstract

Objective

To determine how frequently the appendix harbors pathology in women having surgery for mucinous neoplasms of the ovary and assess the associated morbidity.

Study Design

A retrospective chart review of patients operated upon at our institution with the diagnosis of a mucinous neoplasm of the ovary or appendix.

Results

A total of 327 cases were identified. Of the 309 women with mucinous ovarian neoplasms, 197 (64%) were benign, 68 (22%) LMP, and 44 (14%) were invasive. Out of 155 appendectomies performed, only 1 metastatic low grade mucinous appendiceal tumor was found, but this appendix was grossly abnormal. There was no association between wound complications and appendectomy.

Conclusion

When a grossly normal appendix is removed during surgery for a mucinous ovarian neoplasm without evidence of pseudomyxoma peritonei, no primary or metastatic mucinous appendiceal tumors were found.

Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred - (Lynch Syndrome)



Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred  Pediatric Blood & Cancer 


Abstract

Background

Heterozygous germline mutations in DNA mismatch repair (MMR) genes cause Lynch syndrome. Biallelic MMR mutations cause a distinct syndrome characterized by brain tumors, lymphoid malignancies, and gastrointestinal cancers during childhood. These children usually succumb to multiple cancers before adulthood. We developed a surveillance protocol aiming at early detection for these individuals and report the 10-year experience with a kindred.

Methods

On the basis of genetic testing and early age tumors, the kindred started a cancer surveillance protocol based on the crude estimates of cancer risks and available cancer screening: imaging, endoscopy, and hematologic tests.

Results

Over the 10-year follow-up period, the screening protocol detected 15 tumors. These included three high-grade adenomatous colonic polyps and two colon cancers. In one child, MRI revealed an asymptomatic anaplastic astrocytoma which was treated by complete resection and radiation. All three cancers identified during surveillance were small and asymptomatic at diagnosis. The two sisters are currently 16 and 18 years of age with no evidence of malignant disease. Both parents have annual colonoscopies and the father at 43 years had two colonic adenomatous polyps.

Conclusions

We report on the long-term outcome in patients with biallelic MMR mutations who benefited from prophylactic cancer surveillance. Genetic screening and subsequent surveillance led to earlier recognition of asymptomatic tumors at stages more amenable to resection and probable cure. Multicenter collaboration and implementation of surveillance guidelines is necessary to further determine genotype–phenotype correlations.

Palliative Chemotherapy for Malignant Ascites Secondary to Ovarian Cancer



Palliative Chemotherapy for Malignant Ascites Secondary to Ovarian Cancer

Sun exposure and risk of epithelial ovarian cancer.



Sun exposure and risk of epithelial ov... [Cancer Causes Control. 2012] - PubMed - NCBI

 Abstract

PURPOSE:

Associations between sun exposure (a primary source of vitamin D) and risk of ovarian cancer have been inconsistent. Furthermore, studies have not investigated whether sun exposure at different periods in the lifetime of a person results in differences in risk associations, and little is known about differences according to histological subtype.

METHODS:

Using a population-based case-control study of 1,334 non-Hispanic white women diagnosed with epithelial ovarian cancer in western Washington State between 2002 and 2009 and 1,679 non-Hispanic white controls, we assessed the relation of epithelial ovarian cancer with constitutional pigmentation characteristics, sun exposure behaviors, and an index of ultraviolet (UV) exposure based on residential history. Information was collected through in-person interviews. Logistic regression was used to compute odds ratios, 95 % confidence intervals, and trend p values (P(trend)).

RESULTS:

We noted no association with residence-based measures of UV exposure or self-reported sun exposure, either over the lifetime or within specific age intervals. Also, we observed little evidence of association between constitutional pigmentation characteristics and risk, save for a suggestion of increased risk among women who reported increased ability to suntan upon prolonged sun exposure (P(trend) = 0.03).

CONCLUSIONS:

Results from this study suggest that sun exposure has little influence on the risk of epithelial ovarian cancer. Additional studies in populations with a wider gradient of sun exposure may yet be warranted.

Ovarian cancer-criteria of response and the timing of regimen change in chemotherapy for ovarian cancer



http://www.google.ca/reader/i/?source=mog&hl=en&gl=ca


Sent from my iPhone

Ovarian carcinomatosis: how the radiologist can help plan the surgical approach





Monday, October 15, 2012

Adobe launches new versions of Reader and Acrobat | Internet & Media - CNET News



Adobe launches new versions of Reader and Acrobat | Internet & Media - CNET News

open access: Advances in oncologic imaging (not specific to ovarian but includes genetics)



Advances in oncologic imaging - Akin - 2012 - CA: A Cancer Journal for Clinicians - Wiley Online Library

National Guideline Clearinghouse | WHO guidelines on drawing blood: best practices in phlebotomy.



National Guideline Clearinghouse | WHO guidelines on drawing blood: best practices in phlebotomy.

Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum - Full Text View - ClinicalTrials.gov



Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum - Full Text View - ClinicalTrials.gov


Responsible Party: ARCAGY/ GINECO GROUP
ClinicalTrials.gov Identifier: NCT01705158     History of Changes
Other Study ID Numbers: MYCA (GINECO-OV220), 2012-001999-10
Study First Received: October 1, 2012
Last Updated: October 11, 2012
Health Authority: France: L’Agence nationale de sécurité du médicament et des produits de santé

Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab - Full Text View - ClinicalTrials.gov



Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab - Full Text View - ClinicalTrials.gov


Study Start Date: October 2012
Estimated Study Completion Date: December 2015

Ottawa Cancer Care | Ottawa Integrated Cancer Care | OICC - Ottawa Integrative Cancer Centre



http://www.oicc.ca/en


Sent from my iPhone

Sunday, October 14, 2012

Genetic markers for ovarian cancer risk: are we close to seeing a clinical impact?



Genetic markers for ovarian cancer risk: are we close to seeing a clinical impact?, Personalized Medicine, Future Medicine

Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer



Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer – A study by the OVCAD consortium

View full text

Abstract

Objective

Comparative proteomics identified the plasma protein afamin as potential biomarker for ovarian cancer (OC). Significantly decreased afamin plasma concentrations in pre-therapeutic OC patients reconstituted to control values after successful tumor surgery. This study evaluates the association of afamin with survival and response to therapy in serous OC patients within the OVCAD consortium project.

Methods

We measured afamin in 215 pre-therapeutic plasma samples, 246 tumor lysates and 109 plasma samples taken six months after finishing platinum-based chemotherapy. Differences in afamin plasma concentrations among FIGO stages were tested by Kruskal Wallis test; association of afamin concentrations with overall and progression-free survival was evaluated using Kaplan-Meier survival plots and multivariate adjusted COX regression analysis.

Results

Pre-therapeutic afamin correlated significantly with FIGO stages (p = 0.012) and was lower in the presence of metastases (p = 0.013) and poorly differentiated OC in patients responding to therapy (p = 0.016). Afamin ≥ 48.0 mg/L was also associated with a lower hazard ratio for recurrent disease as compared to afamin < 48.0 mg/L (p = 0.007). Post-therapeutic afamin ≥ 48 mg/L was positively correlated with overall (p < 0.001) and progression-free (p = 0.012) survival and was lower in non-responders than in responders (p = 0.048). Thus, afamin returned post-therapeutically to values of healthy controls in responders (p < 0.001) but not in non-responders (p = 0.114). Afamin in tumor lysates was lower in poorly differentiated OC than in G 1 + 2 tumors (p = 0.041). Higher afamin concentrations in tumor lysates were associated with increased overall survival (p = 0.003).

Conclusion

These data indicate that afamin is associated with therapy response and survival rate in advanced OC patients.

Highlights

► The plasma protein afamin is evaluated as prognostic tumor marker for ovarian cancer
► Afamin plasma concentrations are associated with response to therapy and survival
► Afamin may therefore serve as therapy monitoring for estimation of disease progression

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer



 Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer

7 advisers resign at embattled Texas cancer agency - media



7 advisers resign at embattled Texas cancer agency

Comments



http://www.thestar.com/iphonecomments/1271031


Sent from my iPhone

Canadians are ready for an adult conversation on Medicare



"This story is frequently told and easily understood. But it's almost completely false......

Canadians are ready for an adult conversation on Medicare

Canada's health-care system is ticking along nicely, Dr. Michael Rachlis says.Dreamstime Over the past two years, Brian Mulroney, former Bank of Canada governor David Dodge and other prominent Canadians have...

Published: Today at 4:00 PM

http://bit.ly/Qm8hJy

This article was sent from thestar.com mobile app.

Canada's health-care system is ticking along nicely, Dr. Michael Rachlis says.Dreamstime
Over the past two years, Brian Mulroney, former Bank of Canada governor David Dodge and other prominent Canadians have called for an "adult conversation on medicare." This month Globe and Mail columnist Jeffrey Simpson became the latest member of the Canadian chattering class to call for a mature deliberation about Canada's favourite social program.

The analysis usually proceeds from a 30-second case for medicare's unaffordability. Medicare might have been well-meant but health costs are rising faster than government revenues and the economy. Governments can't fix medicare's problems without raising taxes, which isn't an option. The only hope is that Canadians will finally have a grown-up conversation about medicare and at least introduce more for-profit care if not dismantle it entirely.

This story is frequently told and easily understood. But it's almost completely false.

Total health-care costs as a share of the economy did rise when the economy tanked in 2008-9 but they have been falling for two years. For the past two years, provincial government health costs have also fallen as a share of GDP and as a share of their overall spending. Far from hitting the forecast 70 per cent, or even 50 per cent of program expenditures, provincial health costs are less than 38 per cent of program spending and falling.

Health care did grow from 33 per cent of program spending in the 1990s to 39 per cent in 2003 but this wasn't so much due to higher health costs as it was due to government cuts to other portfolios. From 2000 to 2011, Canadian governments cut taxes by nearly 6 per cent of GDP amounting to foregone annual revenue of $100 billion. And, contrary to the Canadian chin-wag consensus, Canadians strongly support higher progressive taxes. A spring Forum Institute poll indicated that Ontarians favoured by four to one raising higher earners' income taxes. Even Conservative voters favoured fair taxes by two to one.

But the good news is medicare doesn't need much if any new money or for-profit care. Many examples across the country demonstrate we could almost eliminate waits for doctors and other services through process improvement and system redesign. But Simpson and others seeking the mythical adult discussion hardly mention public sector options. These grownups are either ignorant about Etobicoke's Queensway surgicentre — North America's largest ambulatory surgical facility — or they want to keep us ignorant. The Queensway is part of the Trillium health system, a public hospital.

Unfortunately, medicare's real story doesn't get much air time. Former Saskatchewan premier Tommy Douglas talked all his life about the need for the second stage of medicare. He said the first stage featured public payment for the old system based on treating illness with doctors and hospitals. He said the second stage would highlight a redesigned delivery system focussed on keeping people healthy.

In the 1960s, Douglas and Supreme Court judge and co-founder of medicare Emmett Hall supported salaried doctors working in interdisciplinary teams. However, Douglas maintained that it was too politically difficult to change the way doctors were paid and how they did their work coincidently with pressuring them into public payment. For the rest of his life, he repeatedly warned that if the delivery system was left unreformed, medicare would increasingly fail Canadians and lose political support.

When Canadians hear about the second stage of medicare, they are more than ready for a mature conversation. When they hear about innovations to reduce wait lists, they are ready to eradicate them with public sector solutions. When they hear that public finance is more efficient and that Canadian taxes have been cut by $100 billion, they are ready for medicare to cover drugs and continuing care.

So let's start the grown-up conversation with a real question about access. Best practices across Canada demonstrate that we could see our family doctors within one day, see specialists within one week, and get elective surgery within three months. And we could get this much better care for little or no additional cost. How can we make this happen within the next two years everywhere in this country?

It's true that this won't be an easy. But it's a miracle we got medicare at all. The medical profession, almost all the provinces, and most of the Canadian elite opposed medicare 50 years ago. Fortunately, the Canadian people strongly supported medicare then and they still do. Let's plug into that good will and modernize our health system for the 21st century.

Dr. Michael Rachlis is a health policy analyst and an associate professor at the University of Toronto. www.michaelrachlis.ca



Sent from my iPhone

MyChart - Sunnybrook Hospital (Toronto)



MyChart - Sunnybrook Hospital

update: MyChart.ca - Sunnybrook EHR going mobile Oct 15th



My Chart

Mobile: https://m.mychart.ca/ 

October 16th:

MyChart Mobile coming soon!

Multi-Organ Screening Recommendations in (Lynch Syndrome) Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients - Full Text View - ClinicalTrials.gov



Multi-Organ Screening Recommendations in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients

Assessing the Patient Experience in Cancer Care - Full Text View - ClinicalTrials.gov



Assessing the Patient Experience in Cancer Care - Full Text View - ClinicalTrials.gov

Commentary Health Care Costs: How Do We Decide Value? When Do We Decide? How Do We Particularize the Decisions?






Medscape: BEV: New Standard in Resistant Ovarian Cancer?





BEV: New Standard in Resistant Ovarian Cancer? (mobile format)


Medscape: Movies About Cancer Flawed But Useful





Movies About Cancer Flawed